©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Hypertrophic Agonists Stimulate the Activities of the Protein Kinases c-Raf and A-Raf in Cultured Ventricular Myocytes (*)

(Received for publication, May 22, 1995; and in revised form, August 9, 1995)

Marie A. Bogoyevitch (1)(§) Christopher J. Marshall (2)(¶) Peter H. Sugden (1)

From the  (1)From Cardiac Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London SW3 6LY, United Kingdom and the (2)CRC Centre for Cell and Molecular Biology, Chester Beatty Laboratories, Institute of Cancer Research, London SW3 6JB, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

We detected expression of two Raf isoforms, c-Raf and A-Raf, in neonatal rat heart. Both isoforms phosphorylated, activated, and formed complexes with mitogen-activated protein kinase kinase 1 in vitro. However, these isoforms were differentially activated by hypertrophic stimuli such as peptide growth factors, endothelin-1 (ET1), or 12-O-tetradecanoylphorbol-13-acetate (TPA) that activate the mitogen-activated protein kinase cascade. Exposure of cultured ventricular myocytes to acidic fibroblast growth factor activated c-Raf but not A-Raf. In contrast, TPA produced a sustained activation of A-Raf and only transiently activated c-Raf. ET1 transiently activated both isoforms. TPA and ET1 were the most potent activators of c-Raf and A-Raf. Both utilized protein kinase C-dependent pathways, but stimulation by ET1 was also partially sensitive to pertussis toxin pretreatment. c-Raf was inhibited by activation of cAMP-dependent protein kinase although A-Raf was less affected. Fetal calf serum, phenylephrine, and carbachol were less potent activators of c-Raf and A-Raf. These results demonstrate that A-Raf and c-Raf are differentially regulated and that A-Raf may be an important mediator of mitogen-activated protein kinase cascade activation when cAMP is elevated.


INTRODUCTION

The exposure of cells to mitogenic agents that act through protein tyrosine kinase receptors activates a cascade of protein kinases including c-Raf, mitogen-activated protein kinase kinase (MEK), (^1)and mitogen-activated protein kinases (MAPKs)(1, 2) . This protein kinase cascade provides a link between growth factor stimulation and the transcriptional changes that occur in the cell nucleus(3, 4) . More recently, the activation of receptors coupled to heterotrimeric G-proteins has also been shown to activate MEK, p42, and p44(5, 6) . The upstream events in this signaling cascade may also involve c-Raf(7) . Thus, activation of c-Raf may integrate signals from tyrosine kinase receptors and G-protein-coupled receptors.

c-Raf was originally identified as the cellular homolog of an oncogene of a murine sarcoma virus, but the regulation of c-Raf activity and its role in normal cellular functions have, until recently, remained unclear(8) . c-Raf has been shown to interact directly with Ras.GTP (9, 10, 11, 12) . This interaction translocates c-Raf to the membrane(13, 14) and, coupled with other events that may include phosphorylation, activates c-Raf(15, 16, 17) . Activated c-Raf directly phosphorylates MEK1 on two serine residues within a conserved regulatory region between the ``DFG'' and ``A(/S)PE'' motifs(18) . This identification of MEK1 as a physiological substrate allows assay of Raf activation(14, 19) .

c-Raf may not be the only MEK activator in the eukaryotic cell. Recent studies have shown that c-Raf is not the major upstream activator of MAPKs in rat fibroblasts(20, 21) , adipocytes(22) , and PC12 cells(23, 24) . c-Raf is a member of a family of related protein kinases that includes A-Raf and B-Raf(25, 26, 27) . In contrast to the ubiquitous expression of c-Raf, the expression of A-Raf and B-Raf is restricted (28) . Although the expression of truncated, constitutively active forms of A-Raf and B-Raf leads to activation of MAPK(29) , the regulation of these isoforms has not been well-characterized. It is possible that different Raf isoforms may regulate different cellular events. Thus, B-Raf has been proposed as a major activator of MEK in nerve growth factor-stimulated PC12 cells (24) and brain extracts(30, 31) .

The exposure of ventricular myocytes to growth promoting stimuli such as tumor-promoting phorbol esters, endothelin-1 (ET1), alpha(1)-adrenergic agonists, peptide growth factors, or mechanical stretch activates a series of genetic changes that leads to cell hypertrophy rather than cell division(32, 33) . Many of these agonists have also been shown to activate MEK and MAPK in these cells (34, 35, 36, 37) . Recent studies suggest that the MAPK cascade may play a role in the transcriptional changes associated with hypertrophy(38) . In this study, we have examined the expression and activation of Raf isoforms in cultured neonatal rat ventricular myocytes. We show that ventricular myocytes express c-Raf and A-Raf and that hypertrophic stimuli differentially activate these two Raf isoforms.


EXPERIMENTAL PROCEDURES

Materials

Sprague-Dawley rats were bred in the National Heart and Lung Institute. [-P]ATP was from DuPont NEN. ET1, 12-O-tetradecanoylphorbol-13-acetate (TPA), 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), pertussis toxin, Medium 199 (M199), Dulbecco's modified Eagle's medium (DMEM), n-octyl beta-D-glucopyranoside, protease inhibitors, Protein A-Sepharose, bovine myelin basic protein (MBP), Kemptide, and other biochemicals were purchased from Sigma unless stated otherwise. Culture dishes (Primaria) were from Falcon and heat-inactivated fetal calf serum (FCS) was from Sera-Lab. Other tissue culture products were from Life Technologies, Ltd. Glutathione-Sepharose was from Pharmacia and Ni-NTA-agarose was from Qiagen. Recombinant human acidic fibroblast growth factor (aFGF) was provided by Dr. P. Cummins (Department of Physiology, University of Birmingham, Birmingham, United Kingdom). Affinity-purified antibodies raised against C-terminal peptide sequences of c-Raf (CTLTTSPRLPVF), A-Raf (CLLSAARLVP), and B-Raf (ASPKTPIQAGGYGAFPVH), and the corresponding peptides were from Santa Cruz Biotechnology Inc. Enhanced chemiluminescence (ECL) immunoblotting detection reagents and autoradiography film were from Amersham International. Prestained molecular mass standard proteins and reagents to assay protein by the method of Bradford (39) were from Bio-Rad.

Expression of Recombinant Protein Kinases

Recombinant p42 and MEK1 were expressed as glutathione S-transferase (GST) fusion proteins (18, 40) and were purified by glutathione-Sepharose affinity chromatography. Further purification of the His(6)-tagged GST-MEK1 was achieved by Ni-NTA agarose chromatography(18) . For the assay of MEK phosphorylation by the immunoprecipitated protein kinases, recombinant MEK1 was modified by site-directed mutagenesis to produce GST-MEK1(R97/A291/A385), a catalytically inactive form of MEK1 in which a Lys-residue essential for kinase activity is mutated (Lys Arg) and that also lacks MAPK consensus phosphorylation sequences (Thr Ala and Thr Ala). GST for control experiments was recovered following cleavage of glutathione-Sepharose-bound GST-p42 with thrombin. Recombinant proteins were essentially homogeneous by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Recombinant GST-p42 was stored at -20 °C (50% glycerol, final protein concentration 25 mg/ml) whereas recombinant MEK1 species and GST were stored at -80 °C (5% glycerol, final protein concentration 10 mg/ml).

Immunoprecipitation of Raf Isoforms from Heart or Brain

Hearts from neonatal (1-3-day-old) rats were rapidly removed and washed in cold Ca/Mg-free Dulbecco's phosphate-buffered saline (PBS). The ventricular tissue was frozen in liquid N(2), powdered, and then resuspended in a hand-held ground-glass homogenizer in four volumes of Buffer A (10 mM Tris-HCl, 5 mM EDTA, 50 mM NaF, 50 mM NaCl (pH 7.4) containing 1% (v/v) Triton X-100, 20 mMn-octyl beta-D-glucopyranoside, 0.1% (w/v) fatty acid-free bovine serum albumin, 20 µg/ml aprotinin, and 2 mM Na(3)VO(4)). After incubation (10 min) on ice, the lysate was centrifuged (10,000 times g, 10 min, 4 °C). Antibodies against A-Raf, B-Raf, or c-Raf (1/30 final dilution) were added to samples of the supernatants. After incubation with mixing at 4 °C for 2 h, Protein A-Sepharose (1:1 in Buffer A) was added and the incubation continued for 1 h at 4 °C. The Protein A-Sepharose was washed three times in Buffer A, then twice in Buffer B (50 mM Tris-HCl, 0.1 mM EGTA containing 0.5 mM Na(3)VO(4), and 0.1% (v/v) mercaptoethanol). SDS-PAGE sample buffer (37) was added to the supernatant and the washed Protein A-Sepharose pellet. To further examine the expression of B-Raf, adult brain samples were prepared in the same manner. Protein concentrations in the supernatants of resuspended tissue powders were estimated from tissue powders resuspended in bovine serum albumin-free Buffer A.

Interaction of Cellular Proteins with MEK1

Supernatants from detergent-solubilized heart homogenates were prepared as described in the preceding section. GST-MEK1(R97/A291/A385) (0.3 mg, 5 nmol) was added to the supernatants (approximately 10 mg protein/ml). After incubation with continuous mixing at 4 °C for 2 h, glutathione-Sepharose (1:1 in Buffer A) was added and the incubation continued for a further 1 h at 4 °C. The glutathione-Sepharose was washed three times in Buffer A, then twice in Buffer B (50 mM Tris-HCl, 0.1 mM EGTA (pH 7.5) containing 0.5 mM Na(3)VO(4) and 0.1% (v/v) mercaptoethanol). SDS-PAGE sample buffer was added to the supernatant and the washed glutathione-Sepharose pellet.

Immunoblot Analysis

All samples were boiled in SDS-PAGE sample buffer for 5 min. Proteins were separated by SDS-PAGE (10% polyacrylamide gels), then transferred to nitrocellulose. The membranes were probed with antibodies to Raf isoforms (1/100 final dilution in 5% (w/v) non-fat milk in PBS containing 0.05% (v/v) Tween-20) overnight at 4 °C and developed using the ECL method(37) .

Ventricular Myocyte Cultures

Myocytes were dissociated from the ventricles of neonatal rat hearts, resuspended in DMEM/M199 (4:1, v/v) supplemented with 10% horse serum, 5% FCS, and 100 units/ml penicillin and streptomycin, then plated at a final density of 1.4 times 10^3 cells/mm^2 on gelatin-precoated 60-mm dishes(41) . After culture for 18 h at 37 °C in a humidified atmosphere of 5% CO(2), myocytes were confluent and spontaneously beating. Serum was withdrawn for 24 h before the cells were further treated. When indicated, pertussis toxin was added to a final concentration of 150 ng/ml, or TPA was added to a final concentration of 1 µM in the serum-free medium, for 24 h before exposure of myocytes to agonists.

Immunoprecipitation of A-Raf and c-Raf from Cultured Ventricular Myocytes

Serum-starved ventricular myocytes were exposed to agonists in serum-free medium (DMEM/M199) or to 20% (v/v) FCS in DMEM/M199. The medium was aspirated, the cells were washed three times in cold Ca/Mg-free Dulbecco's PBS and scraped into 200 µl of Buffer A. After incubation on ice for 10 min, lysates were centrifuged (10,000 times g, 10 min, 4 °C). In control experiments, we determined that the detergent-insoluble pellets did not contain Raf isoforms as assessed by immunoblotting. The pellets were not analyzed further.

The detergent-soluble supernatants (approximately 1.5-2.0 mg protein/ml) were retained. When activation of A-Raf was directly compared to activation of c-Raf, each supernatant was divided equally. Antibodies that recognize c-Raf or A-Raf (3 µl) were added to each aliquot (90 µl) and these incubated with mixing at 4 °C for 2 h. Protein A-Sepharose was added, and the incubation was continued for 1 h. The immunoprecipitates were washed three times with Buffer A and twice with Buffer B.

Activation of MEK by Immunoprecipitated c-Raf and A-Raf

Protein A-Sepharose immunoprecipitates of c-Raf and A-Raf were assayed for their activation of recombinant GST-MEK1(18, 42) using a coupled assay in which GST-MEK1 activates GST-p42. The activity of GST-p42 is subsequently measured by incorporation of P from [-P]ATP into MBP. Immunoprecipitates were resuspended in 30 µl of Buffer C (30 mM Tris-HCl, 0.1 mM EGTA (pH 7.5) containing 0.1% (v/v) mercaptoethanol, 0.03% (w/v) Brij 35, 10 mM magnesium acetate, and 20 mMn-octyl beta-D-glucopyranoside) that had been supplemented with 200 µM (unlabeled) ATP, 2 µg/ml GST-MEK1, and 20 µg/ml GST-p42. The reactions were incubated at 30 °C for 20 min with intermittent mixing, then terminated by mixing 15 µl of the supernatant with 15 µl of ice-cold Buffer B containing 1 mg/ml bovine serum albumin. The pellets were retained for immunoblotting. The diluted supernatants (10 µl) were mixed with 40 µl of MBP phosphorylation buffer (50 mM Tris-HCl, 0.1 mM EGTA (pH 8.0) containing 0.4 mg/ml MBP, 50 µM ATP, 12.5 mM magnesium acetate, and 1 µCi of [-P]ATP) to assay activity of GST-p42. The reaction was continued for 15 min at 30 °C, then terminated by spotting onto P81 paper and washing four times in 75 mM phosphoric acid. Reactions in which antibodies were incubated with Buffer A and Protein A-Sepharose and then used in the GST-MEK1/GST-p42 activation assay were always performed. These results were subtracted. One unit of Raf activity is that amount in each immunoprecipitation which, in the 20 min incubation in the presence of GST-MEK1, GST-p42, and unlabeled ATP, catalyzed the activation of sufficient GST-p42 to transfer 1 fmol of phosphate from [-P]ATP into MBP/min in the second stage of the assay. Preliminary experiments showed that no activity from TPA-, ET1-, or FCS-stimulated cells was associated with the Protein A-Sepharose after incubation of these detergent-soluble lysates with Protein A-Sepharose in the absence of antibodies to c-Raf or A-Raf. ``In-gel'' assays using MBP polymerized in SDS-PAGE gels (34, 37) confirmed that phosphorylation of MBP in the second stage of the assay was catalyzed by GST-p42 (69 kDa) and not by carry-over of endogenous MAPKs (42 and 44 kDa).

Phosphorylation of MEK1 by Immunoprecipitated c-Raf and A-Raf

Protein A-Sepharose immunoprecipitates of c-Raf and A-Raf were resuspended in 30 µl of Buffer C containing 50 µM ATP, 1 mg/ml GST-MEK1(R97/A291/A385) and 2 µCi of [-P]ATP. The reaction was incubated at 30 °C for 20 min with intermittent mixing. The reaction was stopped by centrifuging the immunoprecipitated kinases from the reaction mixture, then pipetteting 15 µl of the supernatant into SDS-PAGE sample buffer. Samples were boiled for 5 min and separated by electrophoresis on 10% SDS-polyacrylamide gels. The gels were stained, dried, and subjected to autoradiography. Preliminary experiments showed that, in the absence of antibodies to c-Raf or A-Raf, no MEK phosphorylation activity from detergent-soluble lysates of TPA- or ET1-stimulated cells was associated with the Protein A-Sepharose.

Assay of cAMP-dependent Protein Kinase Activity

Cultured myocytes were exposed for 3 min to either serum-free medium or to 100 µM CPT-cAMP in serum-free medium at 37 °C, then washed with cold Ca/Mg-free Dulbecco's PBS and scraped into cold cAMP-dependent protein kinase (PKA) extraction buffer (10 mM NaH(2)PO(4)/Na(2)HPO(4), 1 mM EDTA (pH 6.8) containing 0.2 mM 1-methyl-3-isobutylxanthine, 1 mM dithiothreitol, 100 mM NaCl). Lysates were centrifuged (10,000 times g, 5 min, 4 °C), and the supernatants were assayed for PKA activity using 70 µM Kemptide in the absence and the presence of 2 µM cAMP(43) . Activity ratios were calculated as the ratio of the PKA activity of the sample in the absence of cAMP to that in the presence of 2 µM cAMP.

Expression of Results

Data presented are expressed either as means ± S.E. for the number of independent experiments (n) indicated or as examples of representative experiments, these being performed on at least three independent occasions.


RESULTS

Expression of Raf Isoforms in Ventricular Tissue

Because agonists that cause hypertrophy of the ventricular myocyte activate the MAPK cascade(34, 37) , we investigated the expression and regulation of activators of MEK in the heart. Immunoprecipitation of Raf isoforms with affinity-purified antibodies followed by immunoblotting demonstrated the expression of c-Raf (Fig. 1A, lane 1) and A-Raf (Fig. 1B, lane 3) in the ventricles of neonatal rat hearts. Molecular masses of c-Raf and A-Raf were 74 and 68 kDa, respectively. B-Raf could be detected as a 97-kDa doublet in rat brain (Fig. 1C, lane 1) but not in ventricular tissue (Fig. 1C, lane 3). This result for the pattern of Raf isoform expression in the heart agrees with results from Northern analysis(28) .


Figure 1: Neonatal rat heart ventricles express c-Raf and A-Raf, but not B-Raf. Proteins were separated by SDS-PAGE and transferred to nitrocellulose as described under ``Experimental Procedures.'' The nitrocellulose membranes were probed with antibodies to c-Raf (panels A and D) or A-Raf (panels B and E) or B-Raf (panel C), and the blots were developed using the ECL method. A and B, detergent-soluble extracts of neonatal rat ventricles (approximately 10 mg protein/ml) were incubated with antibodies to c-Raf (lanes 1 and 2) or A-Raf (lanes 3 and 4) at a final concentration of 5 µg/ml as described under ``Experimental Procedures.'' In lanes 2 and 4, the appropriate competing peptide immunogen (c-Raf in lanes 2 and A-Raf in lanes 4) was added at a final concentration of 2 µg/ml. C, detergent-soluble extracts (approximately 10 mg protein/ml) of adult rat brain (lanes 1 and 2) or neonatal rat ventricles (lanes 3 and 4) were incubated with antibodies to B-Raf at a final concentration of 5 µg/ml. In lanes 2 and 4, the B-Raf competing peptide immunogen was added at a final concentration of 2 µg/ml. D and E, detergent-soluble extracts of neonatal rat ventricles (approximately 10 mg protein/ml) were incubated with antibodies to c-Raf (panel D, lanes 1 and 2) or A-Raf (panel E, lanes 1 and 2). The proteins associated with the antibodies are shown in lanes 1 and 2 or those remaining in the supernatant are shown in lanes 1` and 2`. In lanes 2 and 2`, the appropriate competing peptide immunogen was added at a final concentration of 2 µg/ml. The molecular masses (kilodaltons) of standard proteins are shown to the left of each panel. The specific bands for c-Raf, A-Raf, and B-Raf are indicated by the arrows to the right of each panel. Experiments were carried out on three separate occasions with similar results.



The specificity of the immunoreactions was assessed by a number of procedures. First, inclusion of the appropriate immunogenic peptide during the immunoprecipitation procedure competed with Raf binding to the antibody (Fig. 1A, lane 2; Fig. 1B, lane 4). Second, incubation of blots with antibody and the appropriate immunogenic peptide prevented the binding of the antibody to the cognate Raf protein (results not shown). Third, there was no cross-reaction of the c-Raf immunoblotting antibody with the protein immunoprecipitated by the A-Raf antibody (Fig. 1A, lane 3) nor was there cross-reaction of the A-Raf immunoblotting antibody with the protein immunoprecipitated by the c-Raf antibody (Fig. 1B, lane 1). Finally, immunoprecipitation cleared >90% of c-Raf (Fig. 1D) or A-Raf (Fig. 1E) from the extracts.

Interaction of c-Raf and A-Raf with MEK1

c-Raf forms a stable complex with MEK1 that is not dependent on the kinase activities of either protein(44) . To determine if A-Raf, as well as c-Raf, would interact with MEK1, we incubated kinase-inactive GST-MEK1(R97/A291/A385) with detergent-soluble extracts of ventricular tissue. The resulting complexes were precipitated with glutathione-Sepharose and immunoblotted with antibodies to c-Raf and A-Raf. Both c-Raf and A-Raf associated with GST-MEK1 (Fig. 2, A and B, respectively, lane 1). There was no cross-reaction of either antibody with GST-MEK1 incubated in Buffer A alone (Fig. 2, A and B, lane 2). GST alone (Fig. 2, A and B, lane 3) or glutathione-Sepharose (Fig. 2, A and B, lane 4) did not interact with the Raf isoforms. When the corresponding supernatants were immunoblotted, there was loss of Raf only from the supernatant incubated with GST-MEK1 (Fig. 2, A and B, compare lanes 1` and 4`). GST did not deplete the Raf isoforms (Fig. 2, A and B, compare lanes 3` and 4`), and there was no reaction of either antibody with the supernatant of MEK1-GST incubated with Buffer A (Fig. 2, A and B, lane 2`).


Figure 2: c-Raf and A-Raf from neonatal rat heart ventricles interact with MEK1. Detergent-soluble extracts of neonatal rat ventricles (approximately 10 mg protein/ml) were incubated with 0.3 mg (5 nmol) of GST-MEK1(R97/A291/A385) (lanes 1), 0.1 mg (5 nmol) of GST (lanes 3), or buffer in the place of these proteins (lanes 4) as described under ``Experimental Procedures.'' In addition, 0.3 mg of GST-MEK1(R97/A291/A385) was incubated with buffer alone (lanes 2). The proteins associated with subsequently added glutathione-Sepharose (lanes 1-4) or remaining in the supernatant (lanes 1`-4`) were separated by SDS-PAGE and transferred to nitrocellulose. The nitrocellulose membranes were probed with antibodies to c-Raf (panel A) or A-Raf (panel B), and the blots were developed using the ECL method. The molecular masses (kilodaltons) of standard proteins are shown to the left of each panel. The specific bands for c-Raf and A-Raf are indicated by arrows to the right of each panel. Experiments were carried out on three separate occasions with similar results.



ET1 Activates c-Raf and A-Raf in Cultured Ventricular Myocytes

c-Raf is activated after exposure of a variety of cells to growth factors that act through protein tyrosine kinase receptors (45, 46) and G-protein receptors(47) . We examined the ability of ET1, which acts through G-protein-coupled receptors (48) and activates MEK and MAPK(34, 37) , to activate c-Raf in the ventricular myocyte. ET1 (100 nM) activated c-Raf as shown by its ability to activate GST-MEK1 in a coupled assay in vitro (Fig. 3A, closed symbols). Peak activation occurred at 1.5-3 min and had decreased to control levels within 10-30 min (8 ± 3% of peak activity after 30 min exposure, n = 5). There was no detectable activity in c-Raf or A-Raf immunoprecipitated from serum-starved ventricular myocytes exposed to serum-free medium for 1-30 min (results not shown). We confirmed that amounts of c-Raf immunoprecipitated from the extracts of cells used in the time course did not vary greatly (Fig. 3B, upper panel). Activity of immunoprecipitated c-Raf was also assayed by its phosphorylation of a recombinant mutant MEK1, GST-MEK1(R97/A291/A385). The Lys Arg mutation prevents autophosphorylation and the Thr Ala and Thr Ala mutations prevent the ``retrophosphorylation'' of MEK by endogenous MAPK (49) which may be greater than that achieved by c-Raf (50) . This assay confirmed the rapid (within 1 min) and transient activation of immunoprecipitated c-Raf (Fig. 3B, lower panel). A reaction in the absence of immunoprecipitated kinases (Fig. 3, B and C, lanes B) confirmed that there was no autophosphorylation of GST-MEK1(R97/A291/A385).


Figure 3: ET1 activates c-Raf and A-Raf. Cultured ventricular myocytes were treated with 100 nM ET1 (ET) at 37 °C for the times indicated, then A-Raf and c-Raf were immunoprecipitated from the detergent-soluble cell lysates as described under ``Experimental Procedures.'' A, activity of the immunoprecipitated c-Raf (bullet) or A-Raf (circle) was measured in a coupled assay as MEK activating activity. B, the immunoprecipitated c-Raf was immunoblotted (upper panel), and the kinase activity of c-Raf was measured directly by the phosphorylation of GST-MEK1(R97/A291/A385) (lower panel). Blank reactions in which c-Raf antibody was incubated with Buffer A and Protein A-Sepharose, then used in the subsequent assays, were always performed (lane B). The positions of c-Raf and the mutant GST-MEK1 are indicated by the arrows to the right of each panel. C, the immunoprecipitated A-Raf was immunoblotted (upper panel) and the activity of A-Raf was measured directly by the phosphorylation of GST-MEK1 (R97/A291/A385) (lower panel). Blank reactions in which A-Raf antibody was incubated with Buffer A and Protein A-Sepharose, then used in the subsequent assays, were always performed (lane B). The positions of A-Raf and the mutant GST-MEK1 are indicated by the arrows to the right of each panel. Experiments on c-Raf activation were carried out on five separate occasions, and these results were compared with A-Raf activation carried out on three of those five occasions.



We compared the time courses for activation of c-Raf and A-Raf in ET1-stimulated cells. ET1 activated A-Raf measured using the coupled assay (Fig. 3A, open symbols). A-Raf activities were maximal at 3-5 min but were lower than those for c-Raf (49 ± 4% of maximal c-Raf activities, n = 3). A-Raf activity decreased to control levels within 30 min of exposure (21 ± 8% of peak A-Raf activities, n = 3). We confirmed that the amounts of A-Raf immunoprecipitated from these cells did not vary (Fig. 3C, upper panel). The assay of A-Raf by its phosphorylation of GST-MEK1(R97/A291/A385) confirmed that MEK1 is phosphorylated by immunoprecipitated A-Raf (Fig. 3C, lower panel).

TPA Differentially Activates c-Raf and A-Raf

In the ventricular myocyte, TPA activates classical and novel isoforms of PKC (51, 52) and causes sustained activation of MEK (^2)and MAPK(37) . Activation of c-Raf (as measured by the coupled assay) by TPA (1 µM) was rapid and maximal at 3-5 min (Fig. 4A, closed symbols). Activity then fell within 30 min of exposure (32 ± 5% of maximal response, n = 4). This was confirmed in the phosphorylation assay (Fig. 4B). Transient activation of c-Raf in the presence of sustained MEK and MAPK activation has been reported(14) .


Figure 4: TPA differentially activates c-Raf and A-Raf. Cultured ventricular myocytes were treated with 1 µM TPA at 37 °C for the times indicated then A-Raf and c-Raf immunoprecipitated from the detergent-soluble cell lysates as described under ``Experimental Procedures.'' A, activity of the immunoprecipitated c-Raf (bullet) or A-Raf (circle) was measured in a coupled assay as MEK activating activity. The kinase activity of c-Raf (panel B) or A-Raf (panel C) was directly measured by the phosphorylation of GST-MEK1(R97/A291/A385). Blank reactions in which c-Raf antibody (panel B) or A-Raf antibody (panel C) was incubated with Buffer A and Protein A-Sepharose, then used in the subsequent assays, were always performed (lane B). The position of the mutant GST-MEK1 is indicated by the arrow to the right of each panel. Experiments on c-Raf activation were carried out on five separate occasions, and these results were compared with A-Raf activation carried out on three of those five occasions.



A-Raf was also activated as shown by the coupled assay (Fig. 4A, open symbols) or by the direct phosphorylation assay (Fig. 4C). A-Raf was activated to a lesser extent than c-Raf (75 ± 8% of c-Raf activity at 3 min, n = 4) and was slower than c-Raf activation (Fig. 4A, open symbols). Activation of A-Raf was more sustained (69 ± 3% of maximal response at 30 min exposure, n = 4) than the activation of c-Raf so that the activity of A-Raf exceeded that of c-Raf after a 30-min exposure (178 ± 48% of c-Raf activity at 30 min, n = 4).

aFGF Activates c-Raf, but Not A-Raf

aFGF concentrations (25 ng/ml) which maximally activate MAPK and MEK (37) activated c-Raf within 1-3 min (Fig. 5A). The activation of c-Raf was confirmed by the direct phosphorylation of GST-MEK1(R97/A291/A385) (Fig. 5B). A-Raf activation by aFGF was undetectable at any time point examined (Fig. 5A).


Figure 5: aFGF activates c-Raf but not A-Raf. Cultured ventricular myocytes were treated with 25 ng/ml aFGF at 37 °C for the times indicated. A-Raf and c-Raf were then immunoprecipitated from the detergent-soluble cell lysates as described under ``Experimental Procedures.'' A, activity of the immunoprecipitated c-Raf (bullet) or A-Raf (circle) was measured in a coupled assay as MEK activating activity. B, the kinase activity of c-Raf was measured directly by the phosphorylation of GST-MEK1(R97/A291/A385). Blank reactions in which c-Raf antibody was incubated with Buffer A and Protein A-Sepharose, then used in the subsequent assays, were always performed (lane B). The position of the mutant GST-MEK1 is indicated by the arrow at the right of the panel. Experiments on c-Raf activation were carried out on four separate occasions, and these results were compared with A-Raf activation carried out on two of those four occasions.



Comparison of the Stimulation of c-Raf and A-Raf by Agonists

We have identified TPA as a potent activator of MAPK in cultured ventricular myocytes(37) . In this study, TPA was the most potent activator of c-Raf and A-Raf resulting in at least a 10-fold activation of both Raf isoforms (e.g.Fig. 4). Activation of c-Raf by ET1 achieved 90% of the level of TPA stimulation whereas activation by FCS and aFGF was 30-40% of the TPA stimulation (Fig. 6). Phenylephrine and carbachol were the poorest activators examined (Fig. 6). A similar order of potency was observed for A-Raf activation, with the exception that aFGF did not activate A-Raf (Fig. 6).


Figure 6: TPA and ET1 were the most potent activators of c-Raf and A-Raf identified in ventricular myocytes. Cultured ventricular myocytes were treated with 1 µM TPA, 100 nM ET1, 50 µM phenylephrine (PE), 20% (v/v) FCS, 25 ng/ml aFGF (FGF), or 100 µM carbachol (CB) at 37 °C for 3 min. Activity of c-Raf (solid bars) or A-Raf (open bars) immunoprecipitated from the detergent-soluble cell lysates was measured in a coupled assay as MEK activating activity as described under ``Experimental Procedures.'' Results (means ± S.E.) are expressed as a percentage of the TPA response measured on each separate preparation of myocytes and are an average of 3-15 independent observations.



c-Raf and A-Raf Activation by ET1 or TPA Requires Classical and/or Novel PKCs

Prolonged treatment (24 h) with TPA down-regulates classical and novel isoforms of PKC in ventricular myocytes, and this decreases signaling of ET1 to MAPK by 62%(37) . When activities of c-Raf were examined after prolonged TPA pretreatment, basal activities were enhanced (452 ± 54% of values in the absence of TPA pretreatment, n = 3) (Fig. 7A). Similar effects of TPA pretreatment have been reported(53) . This complicated calculation of the inhibition induced by TPA pretreatment. However, the activity of c-Raf elicited by acute ET1 or TPA exposure of TPA-pretreated cells was similar to that of control TPA-pretreated cells (Fig. 7A). These results suggest that pretreatment with TPA down-regulates the subsequent activation of c-Raf by ET1 or TPA and implies participation of classical/novel PKCs. In contrast, FCS produced a small stimulation of c-Raf activity in TPA-pretreated cells (Fig. 7A). This suggests that FCS may activate c-Raf via pathways that are independent of classical/novel PKCs.


Figure 7: Classical and novel PKC isoforms are involved in the activation of c-Raf and A-Raf. Cultured ventricular myocytes were either incubated in serum-free medium (solid or open bars) or pretreated with 1 µM TPA for 24 h (crosshatched or diagonally striped bars), then exposed to serum-free medium (CON), 100 nM ET1, 1 µM TPA, or 20% (v/v) FCS at 37 °C for 3 min. Activity of c-Raf (panel A) or A-Raf (panel B) immunoprecipitated from the detergent-soluble cell lysates was measured in a coupled assay as MEK activating activity as described under ``Experimental Procedures.'' The experiment was performed on three separate occasions with similar results.



In contrast to c-Raf, basal A-Raf activity was not enhanced by TPA pretreatment (Fig. 7B). ET1, TPA, and FCS activation of A-Raf were all decreased by TPA pretreatment, although FCS activation was least sensitive (Fig. 7B). Thus, classical/novel PKCs are essential for TPA and ET1 signaling to A-Raf. FCS may also utilize PKC-independent pathways.

Activation of c-Raf and A-Raf by FCS or ET1 Is Sensitive to Pertussis Toxin

The activation of MAPK by ET1 is largely insensitive to pertussis toxin(41) . Pertussis toxin pretreatment (150 ng/ml) decreased the ET1-stimulation of c-Raf or A-Raf activities by 71 ± 5% (n = 4) or 60 ± 2% (n = 4), respectively (Fig. 8, A and B). Activation of c-Raf or A-Raf by FCS was also decreased by 68 ± 2% (n = 3) and 93 ± 4% (n = 3), respectively (Fig. 8, A and B). In contrast, activation of c-Raf or A-Raf by TPA was decreased by only 19 ± 6% (n = 3) or 27 ± 8% (n = 3), respectively (Fig. 8, A and B). These results suggest that ET1 and FCS use pertussis toxin-sensitive G-proteins in the activation of A-Raf and c-Raf.


Figure 8: Pertussis toxin inhibits activation of c-Raf and A-Raf by ET1 and FCS. Cultured ventricular myocytes were either incubated in serum-free medium (solid or open bars) or pretreated with 150 ng/ml pertussis toxin for 24 h (crosshatched or diagonally striped bars), then exposed to serum-free medium (CON), 100 nM ET1, 1 µM TPA, or 20% (v/v) FCS at 37 °C for 3 min. Activity of c-Raf (panel A) or A-Raf (panel B) immunoprecipitated from the detergent-soluble cell lysates was measured in a coupled assay as MEK activating activity as described under ``Experimental Procedures.'' The experiment was performed on three separate occasions with similar results.



Activation of c-Raf by ET1 Is Inhibited by Activation of PKA

Although activation of PKA can inhibit the MAPK signaling pathway in some cells(54) , activation of MAPK by ET1 (100 nM) in the ventricular myocyte is largely insensitive to inhibition by simultaneous PKA activation. (^3)We investigated whether PKA could inhibit the activation of c-Raf and A-Raf isoforms upon exposure of ventricular myocytes to ET1. Exposure of myocytes to CPT-cAMP (100 µM) increased the PKA activity ratio from 0.10 ± 0.04 (n = 3) to 0.78 ± 0.04 (n = 3) within 1 min. PKA activity was sustained at 3 min (PKA activity ratio, 0.89 ± 0.03, n = 3) and did not alter basal c-Raf or A-Raf activity (Fig. 9). Exposure to 100 µM CPT-cAMP decreased activation of c-Raf by ET1 by 89 ± 5% (n = 4) (Fig. 9). Activation of A-Raf was decreased by only 33 ± 14% (n = 4) (Fig. 9). c-Raf activity in cells exposed to ET1 alone was 210 ± 45% (n = 4) of the activity of A-Raf. After CPT-cAMP exposure, the activity of A-Raf in ET1-stimulated cells was 240 ± 9% (n = 4) of the activity of c-Raf. This suggests that A-Raf provides a signaling pathway to MAPK in the presence of activated PKA.


Figure 9: Elevated PKA activity preferentially inhibits activation of c-Raf by ET1. Cultured ventricular myocytes were treated with serum-free medium (CON), 100 µM CPT-cAMP, 100 nM ET1 (ET) or with 100 µM CPT-cAMP in the presence of 100 nM ET1 (CPT-cAMP + ET) at 37 °C for 3 min. Activity of c-Raf (solid bars) or A-Raf (open bars) immunoprecipitated from the detergent-soluble cell lysates was measured in a coupled assay as MEK activating activity as described under ``Experimental Procedures.'' The experiment was performed on four separate occasions with similar results.




DISCUSSION

The Role of the MAPK Cascade in Cardiac Hypertrophy

The ventricular myocyte responds to growth-promoting stimuli by changes in gene expression and an increase in cell size (hypertrophy) in the absence of cell division(32) . We have proposed that activation of the MAPK pathway may be involved(34, 37) . Direct support for this hypothesis has come from studies in which transfection of ventricular myocytes with Ras(V12) (55) and constitutively activated forms of MEK (^4)produce changes in gene expression qualitatively similar to those observed after treatment with hypertrophic agonists(32) . Furthermore, Ras (55) and MAPK(38, 57) appear to be necessary for phenylephrine-stimulated changes in gene expression.

Two protein kinase activators of MEK have been identified in somatic cells, namely Raf and MEKK(1, 58) . Although both Raf and MEKK may act downstream of Ras(59, 60) , recent evidence indicates that MEKK participates in the activation of stress-activated protein kinase pathways(61, 62, 63) . Either Raf or MEKK may be important in the regulation of the Ras-dependent hypertrophic responses previously observed(55) , but recent studies have demonstrated changes in gene expression typical of the hypertrophic response after transfection with activated forms of c-Raf(64) .

Differential Activation of Raf Isoforms

The activation of c-Raf has been identified as an important event linking the membrane-associated signaling events (such as activation of Ras) with the stimulation of a cascade of cytosolic Ser/Thr protein kinases(59, 65) . Recent studies have addressed the differences in regulation of activation of c-Raf and B-Raf(23, 30, 31, 66) . Notably B-Raf, not c-Raf, appears to be a major form of MEK activator identified in brain extracts(30, 31) .

We have observed that exposure of the ventricular myocyte to aFGF activated c-Raf, but not A-Raf. The reason for this differential activation of Raf isoforms by aFGF is unclear and requires further investigation. The functional effectors of Raf in addition to Ras and Src remain to be identified(15, 16, 17) . Although lipids may interact with the Cys-rich Zn finger of the Raf molecule, diacylglycerol and phosphatidylserine do not appear to activate c-Raf in vitro(67) . Recently, c-Raf activity has shown to be further enhanced by a lipid factor(68) . It may be that the differential activation of A-Raf and c-Raf reflects different requirements for effectors (either species or concentrations). The interaction of c-Raf with other proteins has been suggested(14) . Thus, 14-3-3 proteins interact with c-Raf(69) , and this prevents the deactivation of c-Raf by phosphatases(70) .

The activation of c-Raf by ET1 in ventricular myocytes was sensitive to inhibition by PKA. This is consistent with previous studies which demonstrated the inhibition of the MAPK pathway by PKA(71, 72, 73, 74, 75) . Ser of c-Raf is directly phosphorylated by PKA, and this decreases the affinity of interaction between Ras and c-Raf (71) . This provides negative regulation of c-Raf activity and cross-talk between signal transduction cascades(54) . The N-terminal regions of both B-Raf and A-Raf do not have a site analogous to this consensus PKA phosphorylation site(25, 26) . However, B-Raf is also inhibited by PKA activation(23) , and other sites of phosphorylation (such as in the kinase domain) may also contribute to the PKA-mediated inhibition of c-Raf (76) and possibly B-Raf. We found that A-Raf was less sensitive than c-Raf to inhibition by PKA. The activation of MAPK by ET1 is also relatively insensitive to inhibition by PKA in ventricular myocytes,^2 and A-Raf potentially provides a signaling pathway for MAPK activation that is not inhibited when cAMP concentrations are elevated.

A Role for PKC in the Regulation of c-Raf and A-Raf

The mechanism of activation of the MAPK signaling cascade by phorbol esters and G-protein-coupled receptors remains unclear(77) . The elucidation of this pathway may be especially important in the ventricular myocyte where these agents produce the greatest hypertrophic responses (78, 79, 80, 81) and the largest increases in MEK and MAPK activities (34, 37, 41, 82) .

TPA was the most potent activator of both c-Raf and A-Raf in cultured ventricular myocytes. The activation of c-Raf was rapid and transient whereas activation of A-Raf was slower and sustained. Because the classical and novel isoforms of PKC are major targets of phorbol ester action in the eukaryotic cell(83) , a role for PKC in the activation of both Raf isoforms is implied. In ventricular myocytes, activation of PKC-alpha, PKC-, and PKC- by TPA is rapid (<30 s for maximal response(52, 84) ) and precedes activation of A-Raf or c-Raf. A number of studies have demonstrated activation of c-Raf by PKC(85, 86, 87) , and PKC-alpha directly activates c-Raf by phosphorylation of Ser499(87) which lies within a regulatory region between the ``DFG'' and ``A(/S)PE'' motifs(88) . A-Raf does not have a residue analogous to Ser, and its direct regulation by PKC has not been examined.

Both c-Raf and A-Raf have been identified to interact specifically with HRas after screening a randomly primed mouse embryo cDNA library in the yeast-two hybrid system(10) . An alternative route of Raf activation may involve a PKC-dependent activation of Ras (e.g. activation of Ras guanine nucleotide exchange factors to promote formation of Ras.GTP)(89) . Other sites for PKC-independent actions of phorbol esters cannot be ruled out(90, 91) . Differences in the mechanism of activation of c-Raf and A-Raf by phorbol esters may help to explain the differences in their time courses of activation.

Exposure of ventricular myocytes to ET1, a potent hypertrophic agonist (80, 81) , leads to rapid (within 30 s) stimulation of hydrolysis of membrane phosphatidylinositols(37) ,^2 equally rapid activation of PKC- and PKC-(92) , and activation of MEK and MAPK (34, 37, 92) . ET1 activated c-Raf and A-Raf to 70-90% of the levels achieved by TPA. Both Raf isoforms followed similar rapid and transient time courses of activation in response to ET1. Depletion of novel and classical PKC isoforms which inhibited the ET1-stimulated MAPK activation (37) also inhibited c-Raf and A-Raf activation. These findings are consistent with a hypothesis that activation of PKC leads to activation of both Raf isoforms. Therefore, there must be a major PKC-dependent pathway from the ET1 receptor to Raf activation in these cells. In addition, ET1 elicits tyrosine phosphorylation of Shc in astrocytes (93) which leads to its association with GRB2 (93) and provides a Ras-dependent mechanism for activation of Raf by endothelin.

PKC-independent Pathways of MAPK Activation

Recent studies on the regulation of the MAPK pathway by G-protein-coupled receptors have focused on regulation via G(77) . The introduction of activated forms of G into Rat 1a fibroblasts stimulates MAPK (5, 94, 95) and beta subunits may also activate the MAPK pathway (96, 97, 98) . Inactivation of G by preincubation of cells with pertussis toxin inhibits activation of the Ras/MAPK pathway by agents such as lysophosphatidic acid, alpha(2)-adrenergic agonists, and thrombin(47, 99, 100) . In earlier studies, we identified carbachol and lysophosphatidic acid as utilizing pertussis toxin-sensitive pathways of MAPK activation in the ventricular myocyte(41) . In this study, carbachol was a poor activator of c-Raf or A-Raf. This result is consistent with the proposal that the agents that signal through the G pathway may signal through activators of MEK other than Raf(5, 77) . In the present study the activation of c-Raf or A-Raf by ET1 or FCS was substantially inhibited by pertussis toxin. This suggests that a G pathway initiated by these agonists may signal to both isoforms of Raf. We cannot distinguish between a role for activated G or beta subunits.

Cross-talk between G(q)- and G(i)-coupled pathways is implied from the findings that pretreatment with either TPA or pertussis toxin down-regulates activation of A-Raf. Thus, activation of PKC downstream from both the stimulation of phosphatidylinositol hydrolysis and G is necessary for activation of A-Raf by ET1. Alternatively, activation of phosphatidylinositol hydrolysis by ET1 may be stimulated through G as well as G. The anomalous activation of c-Raf by TPA pretreatment prevents similar attempts at interpretation.

A potent Raf-independent pathway of MAPK activation is suggested by our studies with phenylephrine which activates MAPK and MEK(34, 57, 92) . Here, we demonstrate that phenylephrine is a poor activator of both A-Raf and c-Raf. Future studies must identify which pathways of activation of MEK are utilized by agonists such as phenylephrine. It is equally important to clarify the different mechanisms of activation of A-Raf and c-Raf and to assess the quantitative contribution of each Raf isoform to activation of the MAPK cascade.


FOOTNOTES

*
This work was supported by a grant from The Wellcome Trust and by the Cancer Research Campaign and the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: CRC Centre for Cell and Molecular Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Rd., London SW3 6JB, United Kingdom.

Gibb Life Research Fellow of the Cancer Research Campaign.

(^1)
The abbreviations used are: MEK, mitogen-activated protein kinase kinase; aFGF, acidic fibroblast growth factor; CPT-cAMP, 8-(4-chlorophenylthio)-cAMP; DMEM, Dulbecco's modified Eagle's medium; ECL, enhanced chemiluminescence; ET1, endothelin-1; FCS, fetal calf serum; GST, glutathione S-transferase; M199, medium 199; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; TPA, 12-O-tetradecanoylphorbol-13-acetate.

(^2)
M. A. Bogoyevitch, A. Clerk, and P. H. Sugden, unpublished results.

(^3)
M. A. Bogoyevitch, M. B. Andersson, J. Gillespie-Brown, A. Clerk, P. E. Glennon, S. J. Fuller, and P. H. Sugden, manuscript submitted for publication.

(^4)
Gillespie-Brown, J., Fuller, S. J., Bogoyevitch, M. A., Cowley, S., and Sugden, P. H.(1995) J. Biol. Chem.270, in press.


REFERENCES

  1. Marshall, C. J. (1994) Curr. Opin. Gen. Dev. 4, 82-89 [Medline] [Order article via Infotrieve]
  2. Roberts, T. M. (1992) Nature 360, 534-535 [CrossRef][Medline] [Order article via Infotrieve]
  3. Blenis, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5889-5892 [Abstract]
  4. Davis, R. J. (1993) J. Biol. Chem. 268, 14553-14556 [Free Full Text]
  5. Gardner, A. M., Vaillancourt, R. R., and Johnson, G. L. (1993) J. Biol. Chem. 268, 17896-17901 [Abstract/Free Full Text]
  6. Winitz, S., Russell, M., Qian, N.-X., Gardner, A., Dwyer, L., and Johnson, G. L. (1993) J. Biol. Chem. 268, 19196-19199 [Abstract/Free Full Text]
  7. Johnson, G. L., and Vaillancourt, R. R. (1994) Curr. Opin. Cell Biol. 6, 230-238 [Medline] [Order article via Infotrieve]
  8. Li, P., Wood, K., Mamon, H., Haser, W., and Roberts, T. (1991) Cell 64, 479-482 [Medline] [Order article via Infotrieve]
  9. Koide, H., Satoh, T., Nakafuku, M., and Kaziro, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8683-8686 [Abstract/Free Full Text]
  10. Votjek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214 [Medline] [Order article via Infotrieve]
  11. Warne, P. H., Rodriguez Viciana, P., and Downward, J. (1993) Nature 364, 352-355 [CrossRef][Medline] [Order article via Infotrieve]
  12. Zhang, X.-f., Settleman, J., Kyriakis, J. M., Takeuchi-Suzuki, E., Elledge, S. J., Marshall, M. S., Bruder, J. T., Rapp, U. R., and Avruch, J. (1993) Nature 364, 308-313 [CrossRef][Medline] [Order article via Infotrieve]
  13. Traverse, S., Cohen, P., Paterson, H., Marshall, C., Rapp, U., and Grand, R. J. A. (1993) Oncogene 8, 3175-3181 [Medline] [Order article via Infotrieve]
  14. Wartmann, M., and Davis, R. J. (1994) J. Biol. Chem. 269, 6695-6701 [Abstract/Free Full Text]
  15. Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414 [CrossRef][Medline] [Order article via Infotrieve]
  16. Stokoe, D., MacDonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. (1994) Science 264, 1463-1467 [Medline] [Order article via Infotrieve]
  17. Marais, R., Light, Y., Paterson, H. F., and Marshall, C. J. (1995) EMBO J. 14, 3136-3145 [Abstract]
  18. Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., and Cowley, S. (1994) EMBO J. 13, 1610-1619 [Abstract]
  19. Kyriakis, J. M., App, H., Zhang, X., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992) Nature 358, 417-421 [CrossRef][Medline] [Order article via Infotrieve]
  20. Kizaka-Kondoh, S., and Okayama, H. (1993) FEBS Lett. 336, 255-258 [CrossRef][Medline] [Order article via Infotrieve]
  21. Zheng, C. F., Ohmichi, M., Saltiel, A. R., and Guan, K. L. (1994) Biochemistry 33, 5595-5599 [Medline] [Order article via Infotrieve]
  22. Haystead, C. M. M., Gregory, P., Shirazi, A., Fadden, P., Mosse, C., Dent, P., and Haystead, T. A. J. (1994) J. Biol. Chem. 269, 12804-12808 [Abstract/Free Full Text]
  23. Vaillancourt, R. R., Gardner, A. M., and Johnson, G. L. (1994) Mol. Cell. Biol. 14, 6522-6530 [Abstract]
  24. Jaiswal, R. K., Moodie, S. A., Wolfman, A., and Landreth, G. E. (1994) Mol. Cell. Biol. 14, 6944-6953 [Abstract]
  25. Daum, G., Eisenmann-Tappe, I., Fries, H.-W., Troppmair, J., and Rapp, U. R. (1994) Trends Biochem. Sci. 19, 474-480 [CrossRef][Medline] [Order article via Infotrieve]
  26. Huleihel, M., Goldsborough, M., Cleveland, J., Gunnell, M., Bonner, T., and Rapp, U. R. (1986) Mol. Cell. Biol. 6, 2655-2662 [Medline] [Order article via Infotrieve]
  27. Ikawa, S., Fukui, M., Ueyama, Y., Tamaoki, N., Yamamoto, T., and Toyoshima, K. (1988) Mol. Cell. Biol. 8, 2651-2654 [Medline] [Order article via Infotrieve]
  28. Storm, S. M., Cleveland, J. L., and Rapp, U. R. (1990) Oncogene 5, 345-351 [Medline] [Order article via Infotrieve]
  29. Troppmair, J., Bruder, J. T., Munoz, H., Lloyd, P. A., Kyriakis, J., Banerjee, P., Avruch, J., and Rapp, U. R. (1994) J. Biol. Chem. 269, 7030-7035 [Abstract/Free Full Text]
  30. Catling, A. D., Reuter, C. W. M., Cox, M. E., Parsons, S. J., and Weber, M. J. (1994) J. Biol. Chem. 269, 30014-30021 [Abstract/Free Full Text]
  31. Moodie, S. A., Paris, M. J., Kolch, W., and Wolfman, A. (1994) Mol. Cell. Biol. 14, 7153-7162 [Abstract]
  32. Chien, K. R., Knowlton, K. U., Zhu, H., and Chien, S. (1991) FASEB J. 5, 3037-3046 [Abstract/Free Full Text]
  33. Schneider, M. D., and Parker, T. G. (1990) Circulation 81, 1443-1456 [Medline] [Order article via Infotrieve]
  34. Bogoyevitch, M. A., Glennon, P. E., and Sugden, P. H. (1993) FEBS Lett. 317, 271-275 [CrossRef][Medline] [Order article via Infotrieve]
  35. Yamazaki, T., Tobe, K., Hoh, E., Maemura, K., Kaida, T., Komuro, I., Tamemoto, H., Kadowaki, T., Nagai, R., and Yazaki, Y. (1993) J. Biol. Chem. 268, 12069-12076 [Abstract/Free Full Text]
  36. Sadoshima, J.-I., and Izumo, S. (1993) EMBO J. 12, 1681-1692 [Abstract]
  37. Bogoyevitch, M. A., Glennon, P. E., Andersson, M. B., Clerk, A., Lazou, A., Marshall, C. J., Parker, P. J., and Sugden, P. H. (1994) J. Biol. Chem. 269, 1110-1119 [Abstract/Free Full Text]
  38. Thorburn, J., Frost, J. A., and Thorburn, A. (1994) J. Cell Biol. 126, 1565-1572 [Abstract]
  39. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  40. Stokoe, D., Campbell, D. G., Nakielny, S., Hidaka, H., Leevers, S. J., Marshall, C., and Cohen, P. (1992) EMBO J. 11, 3985-3994 [Abstract]
  41. Bogoyevitch, M. A., Clerk, A., and Sugden, P. H. (1995) Biochem. J. 309, 437-443 [Medline] [Order article via Infotrieve]
  42. Gomez, N., Traverse, S., and Cohen, P. (1992) FEBS Lett. 314, 461-465 [CrossRef][Medline] [Order article via Infotrieve]
  43. Bogoyevitch, M. A., Fuller, S. J., and Sugden, P. H. (1993) Am. J. Physiol. 265, C1247-C1257
  44. Huang, W., Alessandrini, A., Crews, C. M., and Erikson, R. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10947-10951 [Abstract]
  45. Kyriakis, J. M., Force, T. L., Rapp, U. R., Bonventre, J. V., and Avruch, J. (1993) J. Biol. Chem. 268, 16009-16019 [Abstract/Free Full Text]
  46. Chao, T.-S. O., Foster, D. A., Rapp, U. R., and Rosner, M. R. (1994) J. Biol. Chem. 269, 7337-7341 [Abstract/Free Full Text]
  47. Howe, L. R., and Marshall, C. J. (1993) J. Biol. Chem. 268, 20717-20720 [Abstract/Free Full Text]
  48. Sakurai, T., Yanagisawa, M., and Masaki, T. (1992) Trends Pharmacol. Sci. 13, 103-108 [CrossRef][Medline] [Order article via Infotrieve]
  49. Brunet, A., Pagès, G., and Pouysségur, J. (1994) FEBS Lett. 346, 299-303 [CrossRef][Medline] [Order article via Infotrieve]
  50. Saito, Y., Gomez, N., Campbell, D. G., Ashworth, A., Marshall, C. J., and Cohen, P. (1994) FEBS Lett. 341, 119-124 [CrossRef][Medline] [Order article via Infotrieve]
  51. Rybin, V. O., and Steinberg, S. F. (1994) Circ. Res. 74, 299-309 [Abstract]
  52. Pucéat, M., Hilal-Dandan, R., Strulovici, B., Brunton, L. L., and Brown, J. H. (1994) J. Biol. Chem. 269, 16938-16944 [Abstract/Free Full Text]
  53. Crespo, P., Xu, N., Daniotti, J. L., Troppmair, J., Rapp, U. R., and Gutkind, J. S. (1994) J. Biol. Chem. 269, 21103-21109 [Abstract/Free Full Text]
  54. Marx, J. (1993) Science 262, 988-990 [Medline] [Order article via Infotrieve]
  55. Thorburn, A., Thorburn, J., Chen, S.-Y., Powers, S., Shubeita, H. E., Feramisco, J. R., and Chien, K. R. (1993) J. Biol. Chem. 268, 2244-2249 [Abstract/Free Full Text]
  56. Hordijk, P. L., Verlaan, I., van Corven, E. J., and Moolenaar, W. H. (1994) J. Biol. Chem. 269, 645-651 [Abstract/Free Full Text]
  57. Thorburn, J., and Thorburn, A. (1994) Biochem. Biophys. Res. Commun. 202, 1586-1591 [CrossRef][Medline] [Order article via Infotrieve]
  58. Lange-Carter, C. A., Pleiman, C. M., Gardner, A. M., Blumer, K. J., and Johnson, G. L. (1993) Science 260, 315-319 [Medline] [Order article via Infotrieve]
  59. Avruch, J., Zhang, X.-f., and Kyriakis, J. M. (1994) Trends Biochem. Sci. 19, 279-284 [CrossRef][Medline] [Order article via Infotrieve]
  60. Lange-Carter, C. A., and Johnson, G. L. (1994) Science 265, 1458-1461 [Medline] [Order article via Infotrieve]
  61. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Dérijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994) Science 266, 1719-1723 [Medline] [Order article via Infotrieve]
  62. Sánchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994) Nature 372, 794-798 [Medline] [Order article via Infotrieve]
  63. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994) Nature 372, 798-800 [Medline] [Order article via Infotrieve]
  64. Thorburn, J., McMahon, M., and Thorburn, A. (1994) J. Biol. Chem. 269, 30580-30586 [Abstract/Free Full Text]
  65. McCormick, F. (1994) Trends Cell Biol. 4, 347-350 [CrossRef]
  66. Traverse, S., and Cohen, P. (1994) FEBS Lett. 350, 13-18 [CrossRef][Medline] [Order article via Infotrieve]
  67. Force, T., Bonventre, J. V., Heidecker, G., Rapp, U., Avruch, J., and Kyriakis, J. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1270-1274 [Abstract]
  68. Dent, P., Reardon, D. B., Morrison, D. K., and Sturgill, T. W. (1995) Mol. Cell. Biol. 15, 4125-4135 [Abstract]
  69. Morrison, D. (1994) Science 266, 56-57 [Medline] [Order article via Infotrieve]
  70. Dent, P., Jelinek, T., Morrison, D. K., Weber, M. J., and Sturgill, T. W. (1995) Science 268, 1902-1906 [Medline] [Order article via Infotrieve]
  71. Wu, J., Jelinek, T., Wolfman, A., Weber, M. J., and Sturgill, T. W. (1993) Science 262, 1065-1069 [Medline] [Order article via Infotrieve]
  72. Cook, S. J., and McCormick, F. (1993) Science 262, 1069-1072 [Medline] [Order article via Infotrieve]
  73. Hordijk, P. L., Verlaan, I., Jalink, K., van Corven, E. J., and Moolenaar, W. H. (1994) J. Biol. Chem. 269, 3534-3538 [Abstract/Free Full Text]
  74. Burgering, B. M. T., Pronk, G. J., van Weeren, P. C., Chardin, P., and Bos, J. L. (1993) EMBO J. 12, 4211-4220 [Abstract]
  75. Sevetson, B. R., Kong, X., and Lawrence, J. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10305-10309 [Abstract]
  76. Häfner, S., Adler, H. S., Mischak, H., Janosch, P., Heidecker, G., Wolfman, A., Pippig, S., Lohse, M., Ueffing, M., and Kolch, W. (1994) Mol. Cell. Biol. 14, 6696-6703 [Abstract]
  77. Johnson, G. L., Gardner, A. M., Lange-Carter, C., Qian, N.-X., Russell, M., and Winitz, S. (1994) J. Cell. Biochem. 54, 415-422 [Medline] [Order article via Infotrieve]
  78. Dunnmon, P. M., Iwaki, K., Henderson, S. A., Sen, A., and Chien, K. R. (1990) J. Mol. Cell. Cardiol. 22, 901-910 [Medline] [Order article via Infotrieve]
  79. Iwaki, K., Sukhatme, V. P., Shubeita, H. E., and Chien, K. R. (1990) J. Biol. Chem. 265, 13809-13817 [Abstract/Free Full Text]
  80. Shubeita, H. E., McDonough, P. M., Harris, A. N., Knowlton, K. U., Glembotski, C. C., Brown, J. H., and Chien, K. R. (1990) J. Biol. Chem. 265, 20555-20562 [Abstract/Free Full Text]
  81. Ito, H., Hirata, Y., Hiroe, M., Tsujino, M., Adachi, S., Takamoto, T., Nitta, M., Taniguchi, K., and Marumo, F. (1991) Circ. Res. 69, 209-215 [Abstract]
  82. Lazou, A., Bogoyevitch, M. A., Clerk, A., Fuller, S. J., Marshall, C. J., and Sugden, P. H. (1994) Circ. Res. 75, 932-941 [Abstract]
  83. Stabel, S., and Parker, P. J. (1991) Pharmac. Ther. 51, 71-95 [CrossRef][Medline] [Order article via Infotrieve]
  84. Clerk, A., Bogoyevitch, M. A., Fuller, S. J., Lazou, A., Parker, P. J., and Sugden, P. H. (1995) Am. J. Physiol. in press
  85. Carroll, M. P., and May, W. S. (1994) J. Biol. Chem. 269, 1249-1256 [Abstract/Free Full Text]
  86. Marquardt, B., Frith, D., and Stabel, S. (1994) Oncogene 9, 3213-3218 [Medline] [Order article via Infotrieve]
  87. Kolch, W., Heidecker, G., Kochs, G., Hummerl, R., Vahidl, H., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U. R. (1993) Nature 364, 249-252 [CrossRef][Medline] [Order article via Infotrieve]
  88. Marshall, C. J. (1994) Nature 367, 686 [CrossRef][Medline] [Order article via Infotrieve]
  89. Satoh, T., Nakafuku, M., and Kaziro, Y. (1992) J. Biol. Chem. 267, 24149-24152 [Free Full Text]
  90. Gulbins, E., Coggeshall, K. M., Baier, G., Telford, D., Langlet, C., Baier-Bitterlich, G., Bonnefoy-Berard, N., Burn, P., Wittinghofer, A., and Altman, A. (1994) Mol. Cell. Biol. 14, 4749-4758 [Abstract]
  91. Gulbins, E., Coggeshall, K. M., Langlet, C., Baier, G., Bonnefoy-Berard, N., Burn, P., Wittinghofer, A., Katzav, S., and Altman, A. (1994) Mol. Cell. Biol. 14, 906-913 [Abstract]
  92. Clerk, A., Bogoyevitch, M. A., Andersson, M. B., and Sugden, P. H. (1994) J. Biol. Chem. 269, 32848-32857 [Abstract/Free Full Text]
  93. Cazaubon, S., Ramos-Morales, F., Fischer, S., Schweighoffer, F., Strosberg, A. D., and Couraud, P.-O. (1994) J. Biol. Chem. 269, 24805-24809 [Abstract/Free Full Text]
  94. Gupta, S. K., Gallego, C., Johnson, G. L., and Heasley, L. E. (1992) J. Biol. Chem. 267, 7987-7990 [Abstract/Free Full Text]
  95. Gallego, C., Gupta, S. K., Heasley, L. E., Qian, N.-X., and Johnson, G. L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7355-7359 [Abstract]
  96. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420 [CrossRef][Medline] [Order article via Infotrieve]
  97. Faure, M., Voyno-Yasentskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854 [Abstract/Free Full Text]
  98. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710 [Abstract/Free Full Text]
  99. van Corven, E. J., Hordijk, P. L., Medema, R. H., Bos, J. L., and Moolenaar, W. H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1257-1261 [Abstract]
  100. Alblas, J., van Corven, E. J., Hordjik, P. L., Milligan, G., and Moolenaar, W. H. (1993) J. Biol. Chem. 268, 22235-22238 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.